Natural Killer (NK) Cells
Are the principal cells responsible for detecting cancer. NK Cell dysfunction increases lifetime risk of cancer. Restoring NK Cell function is the aim of many immunotherapy companies.
INKmune
INKmune is unique. INKmune works within the body to activate the patients own NK cells against multiple forms of cancer.
Unlike other NK Cell treatments that require external manipulations or priming by extrinsic factors (i.e., cytokines) that cause off-target and often toxic side effects, INKmune is administered directly to the patient and activates only the patient’s resting NK cells.
This specificity greatly improves safety. CaRe Prostate is the first cancer immunotherapy trial approved for administration on an outpatient basis.
INKmune is currently being developed for metastatic castration resistant prostate cancer.
Unlike other NK Cell treatments that require external manipulations or priming by extrinsic factors (i.e., cytokines) that cause off-target and often toxic side effects, INKmune is administered directly to the patient and activates only the patient’s resting NK cells.
This specificity greatly improves safety. CaRe Prostate is the first cancer immunotherapy trial approved for administration on an outpatient basis.
INKmune is currently being developed for metastatic castration resistant prostate cancer.
See how INKmune works
INKmune Publications